SGIOY - Shionogi says oral COVID-19 therapy rapidly cleared virus in mid-stage trial

Announcing new Phase 2b results for the company’s experimental COVID-19 therapy, S-217622, Japanese drugmaker Shionogi & Co. (OTCPK:SGIOY) (OTCPK:SGIOF) said that the once-daily oral treatment led to a rapid clearance of the virus in a trial conducted in Asia. The Phase 2b part of the Phase 2/3 trial was a randomized, placebo-controlled, double-blind study designed to evaluate the antiviral effect and clinical symptom improvement of the protease inhibitor among 428 patients with mild/moderate COVID-19 symptoms in Japan and South Korea. According to the company, the data showed that on day four following the third dose of the therapy, the percentage of patients with positive virus levels declined by nearly 90% compared to the placebo. In the treatment arm, the viral shedding also declined by 1-2 days compared to the placebo group. While there was no significant difference in the total score of 12 COVID-19 symptoms between the treatment arms, a

For further details see:

Shionogi says oral COVID-19 therapy rapidly cleared virus in mid-stage trial